financetom
Business
financetom
/
Business
/
Neurocrine's experimental drug misses primary goal in schizophrenia trial
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Neurocrine's experimental drug misses primary goal in schizophrenia trial
Sep 13, 2024 9:05 PM

Sept 12 (Reuters) - Neurocrine Biosciences ( NBIX ) said

its experimental drug did not achieve the primary goal in a

mid-stage trial aimed at improving cognitive function in

patients with schizophrenia.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Coca-Cola Europacific Partners tempers annual revenue forecast on Indonesia weakness
Coca-Cola Europacific Partners tempers annual revenue forecast on Indonesia weakness
Aug 6, 2025
Aug 6 (Reuters) - Coca-Cola Europacific Partners tempered its annual revenue forecast on Wednesday, citing softer demand in Indonesia due to geopolitical tensions in the Middle East and a challenging macroeconomic environment. The bottler, which operates across Western Europe, the Middle East, Australia and New Zealand, said Southeast Asia volumes were hit by brand boycotts in Indonesia, a Muslim-majority country,...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Astera Labs Stock Surges Over 18% During Pre-Market On Record Quarterly Revenue
Astera Labs Stock Surges Over 18% During Pre-Market On Record Quarterly Revenue
Aug 6, 2025
Astera Labs Inc. ( ALAB ) witnessed an 18.73% surge in its stock value during the pre-market session on Wednesday. This came after the company announced its second-quarter financial results, which exceeded market expectations. Check out how ALAB stock is trading here.  What Happened: Astera Labs’ stock price soared to $160.93 in pre-market trading, marking an 18.73% increase from the...
Chemours Q2 Adjusted Earnings, Sales Rise
Chemours Q2 Adjusted Earnings, Sales Rise
Aug 6, 2025
04:32 AM EDT, 08/06/2025 (MT Newswires) -- Chemours ( CC ) reported Q2 adjusted earnings late Tuesday of $0.58 per diluted share, up from $0.38 a year earlier. Analysts polled by FactSet expected $0.46. Sales for the quarter ended June 30 were $1.62 billion, up from $1.55 billion a year earlier. Analysts polled by FactSet expected $1.57 billion. For Q3,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved